Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Items 401–500 of 1,003
Klementová, M., Thieme, L., Haluzík, M., Pavlovičová, R., Hill, M., Pelikánová, T., & Kahleová, H. (2019) · Nutrients · doi:10.3390/nu11010157 · Cited by 81
“Furthermore, the satiety hormones GLP-1 [9], peptide YY (PYY) [10], pancreatic polypeptide (PP) [11] and amylin [12] regulate appetite and energy homeostasis.”
BackgroundDo Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?
Papamargaritis, D., & le Roux, C. W. (2021) · Nutrients · doi:10.3390/nu13030762 · Cited by 68
CCK, PYY and PP: The Control of Energy Balance
Simpson, K. A., Parker, J., Plumer, J., & Bloom, S. R. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_9 · Cited by 73
Self-citationAdvances in nasal drug delivery through tight junction technology
Johnson, P. H., & Quay, S. C. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.2.281 · Cited by 68
“Its derivative, PYY3-36, is a promising therapeutic candidate for the treatment of obesity [103].”
BackgroundHelou, N., Obeid, O., Azar, S. T., & Hwalla, N. (2008) · Annals of Nutrition and Metabolism · doi:10.1159/000138122 · Cited by 68
“This increase was affected by both, the energy content and type of the meal. Hence, PYY was implicated in the regulation of food intake due to these changes in its serum levels following meal ingestion. Batterham et al.[”
BackgroundIntravenous CCK-8, but not GLP-1, suppresses ghrelin and stimulates PYY release in healthy men
Brennan, I. M., Otto, B., Feltrin, K. L., Meyer, J. H., Horowitz, M., & Feinle‐Bisset, C. (2006) · Peptides · doi:10.1016/j.peptides.2006.10.014 · Cited by 74
Neuropeptides: Metabolism to Bioactive Fragments and the Pharmacology of Their Receptors
Hallberg, M. (2014) · Medicinal Research Reviews · doi:10.1002/med.21323 · Cited by 79
Defining the Role of Cholecystokinin in the Lipid-Induced Human Brain Activation Matrix
Lassman, D. J., McKie, S., Gregory, L. J., Lal, S., D’Amato, M., Steele, I. A., Varró, A., Dockray, G. J., Williams, S., & Thompson, D. G. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.060 · Cited by 77
Can Gut Hormones Control Appetite and Prevent Obesity?
Chaudhri, O. B., Wynne, K., & Bloom, S. R. (2008) · Diabetes Care · doi:10.2337/dc08-s269 · Cited by 84
Self-citationBoey, D., Heilbronn, L. K., Sainsbury, A., Laybutt, D. R., Kriketos, A. D., Herzog, H., & Campbell, L. V. (2006) · Neuropeptides · doi:10.1016/j.npep.2006.08.002 · Cited by 68
“Since greater diVerences in circulating PYY levels have been detected between frankly obese and lean subjects in previous studies (Alvarez Bartlolome et al., 2002; Batterham et al., 2003; Roth et al., 2005), it is conceivable that small, very long term deWciencies in PYY may contribute to the development of excess adi…”
BackgroundObese Adolescents Show Impaired Meal Responses of the Appetite‐Regulating Hormones Ghrelin and PYY
Mittelman, S. D., Klier, K., Braun, S., Azen, C. G., Geffner, M. E., & Buchanan, T. A. (2010) · Obesity · doi:10.1038/oby.2009.499 · Cited by 70
“Obese adults have lower fasting levels of PYY, and also demonstrate a blunted response to caloric intake (20,21) compared to lean adults.”
BackgroundLomenick, J. P., Melguizo, M. S., Mitchell, S. L., Summar, M. L., & Anderson, J. W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0949 · Cited by 83
“Serum PYY levels have been shown in adult studies to increase after eating with a peak at 1–2 h (9, 10).”
BackgroundReview: Free fatty acid receptors: emerging targets for treatment of diabetes and its complications
Lee Kennedy, R., Vangaveti, V., Jarrod, G., Shashidhar, V., Shashidhar, V., & Baune, B. T. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810381066 · Cited by 67
“1998], and its release is accompanied by decreased appetite and decreased food intake through actions in the central nervous system [Batterham et al. 2003].”
BackgroundMartin, C. K., Han, H., Anton, S., Greenway, F., & Smith, S. R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091595 · Cited by 69
Neurohormonal Regulation of Appetite and its Relationship with Stress: A Mini Literature Review
Ans, A. H., Anjum, I., Satija, V., Inayat, A., Asghar, Z., Akram, I., & Shrestha, B. (2018) · Cureus · doi:10.7759/cureus.3032 · Cited by 86
Chan, J. L., Stoyneva, V., Kelesidis, T., Raciti, P. M., & Mantzoros, C. S. (2005) · Diabetologia · doi:10.1007/s00125-005-0041-2 · Cited by 76
“Regulation of appetite and body weight requires the complexintegrationofsignals(hormonal,metabolicandneural) deriving from several peripheral organs, including the gutderived peptide YY (PYY) and its cleaved product peptide YY3–36(PYY3–36).PYY3–36hasbeenshowntoreducefood intake over the short term in animals [1, 2] an…”
BackgroundResultInfluentialSignalling in the gut endocrine axis
Gribble, F. M., & Reimann, F. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.02.039 · Cited by 66
“Data from human studies suggest that people with obesity have raised fasting GLP-1 and lower fasting PYY plasma concentrations [64, 65], but whether these changes reflect the influence of different diets or body weight/adiposity is not clear.”
BackgroundSmitka, K., Papežová, H., Vondra, K., Hill, M., Hainer, V., & Nedvidkova, J. (2013) · International Journal of Endocrinology · doi:10.1155/2013/483145 · Cited by 67
“These hypotheses are in keeping with the finding of Hotta et al. [92] who reported decreased levels of plasma acylated ghrelin in AN patients.”
ResultNeuroendocrine dysregulation of food intake in eating disorders
Monteleone, P., Castaldo, E., & Maj, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.007 · Cited by 75
The Cholinergic System Controls Ghrelin Release and Ghrelin-Induced Growth Hormone Release in Humans
Maier, C., Schaller, G., Buranyi, B., Nowotny, P., Geyer, G., Wolzt, M., & Luger, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0656 · Cited by 67
Nunez, D. J., Bush, M. A., Collins, D. A., McMullen, S. L., Gillmor, D., Apseloff, G., Atiee, G., Corsino, L., Morrow, L., & Feldman, P. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092494 · Cited by 65
“in Study 2; presumed to be mainly PYY3–36) should have reduced food intake based on the reported effects of acute PYY3–36 infusion [5,23], yet we did not observe changes in the self-reported hunger, satiety or craving parameters, or estimations of caloric intake.”
BackgroundObesity: Scope, Lifestyle Interventions, and Medical Management
McCafferty, B. J., Hill, J. O., & Gunn, A. J. (2020) · Techniques in vascular and interventional radiology · doi:10.1016/j.tvir.2020.100653 · Cited by 83
Gut microbiota and its metabolites: Bridge of dietary nutrients and obesity-related diseases
Zhou, M., Johnston, L. J., Wu, C., & Ma, X. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1986466 · Cited by 70
Roth, C. L., & Reinehr, T. (2010) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2009.265 · Cited by 75
“Administration of PYY in obese humans has been reported to reduce food intake in the short-term.(117) Several gut hormone–based treatments for obesity are under investigation in phase 2 and 3 clinical trials, and many more are in the pipeline.”
BackgroundBench-to-bedside review: The gut as an endocrine organ in the critically ill
Deane, A. M., Chapman, M. J., Fraser, R. J., & Horowitz, M. (2010) · Critical Care · doi:10.1186/cc9039 · Cited by 66
Peripheral signalling involved in energy homeostasis control
Lancha, A., Frühbeck, G., & Gómez‐Ambrosi, J. (2012) · Nutrition Research Reviews · doi:10.1017/s0954422412000145 · Cited by 74
“Lower levels of PYY3–36 have been reported in obese individuals, suggesting that this gut hormone has a role in the pathophysiology of obesity((319)).”
BackgroundAdams, S. H., Won, W. B., Schonhoff, S. E., Leiter, A. B., & Paterniti, J. R. (2004) · Endocrinology · doi:10.1210/en.2004-0518 · Cited by 66
Walsh, J., & Henriksen, D. B. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.020 · Cited by 71
Low‐dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal‐Weight Subjects
Chapman, I., Parker, B., Doran, S., Feinle‐Bisset, C., Wishart, J., Lush, C. W., Chen, K., LaCerte, C., Burns, C., McKay, R., et al. (2007) · Obesity · doi:10.1038/oby.2007.626 · Cited by 64
“In recent years, the discovery and characterization of novel gastrointestinal peptide hormones, such as ghrelin and peptide YY-3–36 (PYY3–36), 1 have sparked renewed interest concerning the physiologic role of peripheral satiety signals in the complex neuroendocrine control of food intake and body weight (1–5).”
BackgroundDoucet, É., Laviolette, M., Imbeault, P., Strychar, I. M., RABASA-LHORET, R. P. R., & Prud’homme, D. (2008) · Metabolism · doi:10.1016/j.metabol.2008.05.017 · Cited by 74
“This may be explained by the fact that most of the studies that have documented a link between ghrelin [15] and/or PYY [9,32] and appetite scores and EI used exogenous administration of these peptides.”
BackgroundResultPeripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance
Chandarana, K., Gelegen, C., Irvine, E. E., Choudhury, A. I., Amouyal, C., Andreelli, F., Withers, D. J., & Batterham, R. L. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.03.001 · Cited by 65
“In humans, PYY3-36 infusion studies have reported no effect on glucose homeostasis [20–22].”
BackgroundSelf-citationObesity treatment: novel peripheral targets
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 64
Self-citationBizzarri, C., Rigamonti, A. E., Luce, A., Cappa, M., Cella, S. G., Berini, J., Sartório, A., Müller, E. E., & Salvatoni, A. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-1033 · Cited by 64
Gee, J. M., & Johnson, I. T. (2005) · Nutrition · doi:10.1016/j.nut.2005.03.002 · Cited by 64
Farhadipour, M., & Depoortere, I. (2021) · Nutrients · doi:10.3390/nu13061839 · Cited by 75
“Peptide-YY (PYY) L cells (colon) Postprandial rise Anorexigenic Postprandial [43,57,58]”
BackgroundHibi, M., Kubota, C., Mizuno, T., Aritake, S., Mitsui, Y., Katashima, M., & Uchida, S. (2017) · Scientific Reports · doi:10.1038/srep39640 · Cited by 62
Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status
Kumar, M. S. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2019.00011 · Cited by 68
“In literature reports, a gut hormone fragment peptide YY3–36 reduced the hunger and also the intake of food in normal weight subjects (67).”
BackgroundDelgado-Aros, S., Camilleri, M., Castillo, E. J., Cremonini, F., Stephens, D. A., Ferber, I., Baxter, K. L., Burton, D. D., & Zinsmeister, A. R. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00285-5 · Cited by 66
Vella, A., Bock, G., Giesler, P. D., Burton, D. B., Serra, D. B., Saylan, M. L., Deacon, C. F., Foley, J. E., Rizza, R. A., & Camilleri, M. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03235.x · Cited by 61
Olli, K., Salli, K., Alhoniemi, E., Saarinen, M., Ibarra, A., Vasankari, T., Rautonen, N., & Tiihonen, K. (2015) · Nutrition Journal · doi:10.1186/1475-2891-14-2 · Cited by 59
“[68] Postprandial GLP-1 and PYY responses have also been shown to be impaired in obese subjects compared to those of normal weight [19,20].”
BackgroundKöhnke, R., Lindqvist, A., Göransson, N., Emek, S. C., Albertsson, P., Rehfeld, J. F., Hultgårdh‐Nilsson, A., & Erlanson‐Albertsson, C. (2009) · Phytotherapy Research · doi:10.1002/ptr.2855 · Cited by 61
“PYY is known to be released by dietary fat and hence could be a candidate for a fat specific satiety signal (Batterham et al., 2003; Degen et al., 2007).”
BackgroundObesity pharmacotherapy: What is next?
Colon-Gonzalez, F., Kim, G. W., Lin, J. E., Valentino, M. A., & Waldman, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.005 · Cited by 62
“IV infusion of PP (10 pmol/kg/min) in healthy subjects reduced appetite and caloric intake by 22%, and proved effective over 24 hours (Batterham et al., 2003b).”
BackgroundGut endocrine secretions and their relevance to satiety
Dockray, G. J. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.05.005 · Cited by 67
Nausheen, S., Shah, I. H., Pezeshki, A., Sigalet, D. L., & Chelikani, P. K. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00130.2013 · Cited by 67
Neuroimaging, Gut Peptides and Obesity: Novel Studies of the Neurobiology of Appetite
Gibson, C. D., Carnell, S., Ochner, C. N., & Geliebter, A. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.02025.x · Cited by 61
Effects of dietary fatty acid composition from a high fat meal on satiety
Kozimor, A. L., Chang, H., & Cooper, J. A. (2013) · Appetite · doi:10.1016/j.appet.2013.05.006 · Cited by 61
Kuo, Y., Herlihy, A. H., So, P., & Bell, J. D. (2006) · NMR in Biomedicine · doi:10.1002/nbm.1070 · Cited by 75
Martin, N. M., Small, C. J., Sajedi, A., Patterson, M., Ghatei, M. A., & Bloom, S. R. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802646 · Cited by 66
Self-citationHellström, P. M. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835d9ff8 · Cited by 74
Sandberg, J. C., Björck, I., & Nilsson, A. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151985 · Cited by 73
In vivo and in vitro degradation of peptide YY3–36 to inactive peptide YY3–34 in humans
Toräng, S., Bojsen-Møller, K. N., Svane, M. S., Hartmann, B., Rosenkilde, M. M., Madsbad, S., & Holst, J. J. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00394.2015 · Cited by 61
“Anorexigenic effects of PYY3–36 have been demonstrated in several studies with intravenous administration of PYY3–36 (6, 16, 32, 34), whereas infusions of PYY1–36 have no effect on food intake (34), suggesting that the cleavage of PYY1–36 to PYY3–36 is not as complete and rapid as for GLP-1 (34).”
BackgroundRole of motility in chronic diarrhoea
Spiller, R. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00836.x · Cited by 61
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00164.2007 · Cited by 72
“—Peptide YY(3-36) [PYY(3-36)] is a gut-brain peptide that decreases food intake when administered by intravenous infusion to lean and obese humans and rats.”
BackgroundMethodInfluentialGastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications
Cifuentes, L., Camilleri, M., & Acosta, A. (2021) · Nutrients · doi:10.3390/nu13041158 · Cited by 57
Schwartz, A., & Bellissimo, N. (2021) · Appetite · doi:10.1016/j.appet.2021.105260 · Cited by 66
The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes
Adamska, E., Ostrowska, L., Górska, M., & Krętowski, A. (2014) · Gastroenterology Review · doi:10.5114/pg.2014.42498 · Cited by 60
“Previous studies reveal low PYY levels in obese patients [45].”
BackgroundResultBuchwald, H., Dorman, R. B., Rasmus, N. F., Michalek, V. N., Landvik, N. M., & Ikramuddin, S. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.01.032 · Cited by 59
“Curiously, PYY exhibits 2 active circulating forms: PYY (1–36), which essentially increases appetite and promotes weight gain, and PYY (3–36), formed from the cleavage of the tyrosine-proline residues from the N-terminal of the polypeptide, which does the opposite, centrally decreasing appetite and promoting weight lo…”
BackgroundModulation of neuropeptide Y receptors for the treatment of obesity
Sato, N., Ogino, Y., Mashiko, S., & Ando, M. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903251722 · Cited by 66
“followed by several further studies, there have been several attempts to assess the therapeutic potential of PYY3 – 36 in humans [57].”
BackgroundMethodInfluentialMurray, C. D., le Roux, C. W., Emmanuel, A. V., Halket, J. M., Przyborowska, A. M., Kamm, M. A., & Murray‐Lyon, I. M. (2008) · Appetite · doi:10.1016/j.appet.2008.06.012 · Cited by 66
Hormone Changes Affecting Energy Homeostasis after Metabolic Surgery
Harvey, E. J., Arroyo, K., Korner, J., & Inabnet, W. B. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20203 · Cited by 59
Pharmaceutical approaches to the treatment of obesity
Jandacek, R. J., & Woods, S. C. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03244-1 · Cited by 64
Gueugnon, C., Mougin, F., Nguyen, N. U., Bouhaddi, M., Nicolet-Guénat, M., & Dumoulin, G. (2011) · European Journal of Applied Physiology · doi:10.1007/s00421-011-2154-2 · Cited by 66
“This was conWrmed by acute peripheral administration of PYY, which reduced food intake in rodents and humans (Batterham et al. 2002, 2003).”
Obesity, Gut Hormones, and Bariatric Surgery
Pournaras, D. J., & le Roux, C. W. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-0080-9 · Cited by 65
“It has been shown to induce satiety and reduce food intake in both the obese and the non-obese [21, 22 ].”
BackgroundHuang, X., Yu, Y., Beck, E. J., South, T., Li, Y., Batterham, M. J., Tapsell, L. C., & Chen, J. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100095 · Cited by 58
Modulation of taste responsiveness by the satiation hormone peptide YY
La Sala, M. S., Hurtado, M. D., Brown, A. R., Bohórquez, D. V., Liddle, R. A., Herzog, H., Zolotukhin, S., & Dotson, C. D. (2013) · The FASEB Journal · doi:10.1096/fj.13-228064 · Cited by 58
“(21, 22) demonstrated that PYY delivered systemically”
BackgroundHunschede, S., Kubant, R., Akilen, R., Thomas, S. G., & Anderson, G. H. (2017) · Current Developments in Nutrition · doi:10.3945/cdn.116.000398 · Cited by 66
Presence and dynamics of leptin, GLP‐1, and PYY in human breast milk at early postpartum
Schueler, J., Alexander, B. M., Hart, A. M., Austin, K. J., & Larson‐Meyer, D. E. (2013) · Obesity · doi:10.1002/oby.20345 · Cited by 57
“Both hormones are released in response to the presence of nutrients in the intestine (16,17) and, once released, act on appetite centers in the brain to inhibit food intake at subsequent meals (18,19).”
Ghrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants
Kirchner, H., Tong, J., Tschöp, M. H., & Pfluger, P. T. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00191.2009 · Cited by 57
“This discovery could be useful for the therapy of obese humans if PYY levels are low in obesity (11, 65).”
BackgroundCharacterization of brainstem peptide YY (PYY) neurons
Glavas, M. M., Grayson, B. E., Allen, S. E., Copp, D. R., Smith, M. S., Cowley, M. A., & Grove, K. L. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21543 · Cited by 58
“…food intake in rodents (Batterham et al., 2002; Halatchev et al., 2004), nonhuman primates (Koegler et al., 2005; Moran et al., 2005), and humans (Batterham et al., 2002, 2003; Degen et al., 2005), and that this anorexigenic response may be centrally mediated (Batterham et al., 2002;…”
BackgroundGenetic contributors to obesity
McPherson, R. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)71002-4 · Cited by 81
“In contrast, functional studies (26) both in humans and in rodents indicate a potentially important role for PYY in decreasing food intake.”
BackgroundResultWölnerhanssen, B. K., Moran, A. W., Burdyga, G., Meyer‐Gerspach, A. C., Peterli, R., Manz, M., Thumshirn, M., Daly, K., Beglinger, C., & Shirazi‐Beechey, S. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-08487-9 · Cited by 62
Gut microbes and food reward: From the gut to the brain
d’Oplinter, A. D. W., Huwart, S. J. P., Cani, P. D., & Everard, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.947240 · Cited by 59
“Indeed, targeting the endogenous production of GLP-1 and PYY is highly attractive since the levels of these peptides are decreased in obese and diabetic individuals (Ranganath et al., 1996; Mannucci et al., 2000; Verdich et al., 2001; Vilsboll et al., 2001; Batterham et al., 2003; le Roux et al., 2006).”
BackgroundChowdhury, E. A., Richardson, J. D., Tsintzas, K., Thompson, D., & Betts, J. A. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.154 · Cited by 52
Scheid, J. L., & De Souza, M. J. (2010) · Medicine and Sport Science · doi:10.1159/000321974 · Cited by 57
Effect of weight loss by a low-fat diet and a low-carbohydrate diet on peptide YY levels
Essah, P. A., Levy, J. R., Sistrun, S. N., Kelly, S. M., & Nestler, J. E. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.48 · Cited by 54
“Since lower PYY levels are associated with increased appetite (5,7), we speculate that reduced PYY levels following diet-induced weight loss represents a physiological homeostatic mechanism to preserve baseline body weight.”
BackgroundGastrointestinal satiety signals
Chaudhri, O. B., Field, B. C. T., & Bloom, S. R. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.235 · Cited by 68
Self-citationCommon neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men
Lavebratt, C., Alpman, A., Persson, B., Arner, P., & Hoffstedt, J. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0803188 · Cited by 57
Brain somatic cross-talk: Ghrelin, leptin and ultimate challengers of obesity
Popovic, V., & Duntas, L. H. (2005) · Nutritional Neuroscience · doi:10.1080/10284150400027107 · Cited by 57
“The PYY 3–36 infusion reduced hunger in both obese and lean groups (Batterham et al. 2003).”
BackgroundGiménez‐Palop, O., Giménez‐Pérez, G., Mauricio, D., González-Clemente, J. M., Potau, N., Berlanga, E., Trallero, R., Laferrère, B., & Caixàs, A. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02707.x · Cited by 64
El‐Salhy, M., & Hausken, T. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.09.005 · Cited by 55
Gut hormones as therapeutic agents in treatment of diabetes and obesity
Tan, T., & Bloom, S. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.005 · Cited by 66
Self-citationEffect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss
Pournaras, D. J., Aasheim, E. T., Bueter, M., Ahmed, A. R., Welbourn, R., Olbers, T., & le Roux, C. W. (2012) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2012.01.021 · Cited by 55
Catamo, E., Tornese, G., Concas, M. P., Gasparini, P., & Robino, A. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.08.025 · Cited by 56
The Pharmacological Treatment and Management of Obesity
Hussain, S. S., & Bloom, S. R. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2243 · Cited by 54
“Initial studies have utilized an injectable form of PYY 3–36 , which has produced a reduction of food intake in humans.(63) The most commonly known adverse effect is dose-related nausea.”
MethodSelf-citationHuda, M. S. B., Dovey, T. M., Wong, S., English, P., Halford, J. C. G., McCulloch, P. G., Cleator, J., Martin, B., Cashen, J., Hayden, K., et al. (2009) · International Journal of Obesity · doi:10.1038/ijo.2008.270 · Cited by 62
“Indeed, though peptide YY (PYY) and glucagon-like-peptide-1 (GLP-1) are reported to be lower in obese subject”
BackgroundWeber‐Stadlbauer, U., Woods, S. C., Langhans, W., & Meyer, U. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.12.003 · Cited by 61
“This hypothesis is further strengthened by the observation that obese individuals display attenuated circulating levels of PYY (Batterham et al., 2003; Chandarana et al., 2011).”
Ileal transposition provides insight into the effectiveness of gastric bypass surgery
Strader, A. D. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.05.034 · Cited by 53
“Peptide YY is also produced in the L-cells within the ileum of the small intestine and is also implicated in satiety (PYY 3– 36) in rodents and humans [34–36].”
BackgroundSeimon, R. V., Lange, K. M., Little, T. J., Brennan, I. M., Pilichiewicz, A. N., Feltrin, K. L., Smeets, A. J. P. G., Horowitz, M., & Feinle‐Bisset, C. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.29015 · Cited by 54
“The effects of PYY (3–36), the active metabolite of PYY, on energy intake have been the subject of much debate, with a number of studies (5, 43) that reported profound suppressant effects of ’30% in lean and obese humans, whereas extensive studies (18) in rodents showed no such effects.”
BackgroundEffects and mechanisms of auricular vagus nerve stimulation on high-fat-diet—induced obese rats
Li, H., Zhang, J.-B., Xu, C., Tang, Q., Shen, W., Zhou, J., Chen, J., & Wang, Y. (2015) · Nutrition · doi:10.1016/j.nut.2015.05.007 · Cited by 53
“PYY3–36 mainly acts to reduce feeding frequency, postpone initiation of the next meal, and affect satiety rather than satiation [42].”
BackgroundOverweight and Obesity in Children and Adolescents
Bradford, N. (2009) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2009.01.002 · Cited by 73
Sims, H., Smith, K. H., Bramlage, P., & Minguet, J. (2018) · Diabetic Medicine · doi:10.1111/dme.13645 · Cited by 59
Variations in Peptide YY and Y2 Receptor Genes Are Associated With Severe Obesity in Pima Indian Men
Ma, L., Tataranni, P. A., Hanson, R. L., Infante, A. M., Kobes, S., Bogardus, C., & Baier, L. J. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1598 · Cited by 53
“Peripheral administration of PYY3-36 was reported to inhibit food intake in humans (10), and plasma PYY concentrations were decreased in obese compared with lean subjects (10).”
BackgroundTannock, G. W., & Liu, Y. (2019) · Journal of the Royal Society of New Zealand · doi:10.1080/03036758.2019.1657471 · Cited by 59
“Administration of PYY or GLP-1 to humans enhances satiety and reduces food intake (Turton et al. 1996; Batterham et al. 2003).”
BackgroundHow dietary amino acids and high protein diets influence insulin secretion
Yanagisawa, Y. (2023) · Physiological Reports · doi:10.14814/phy2.15577 · Cited by 58
Borg, C.-M., le Roux, C. W., Ghatei, M. A., Bloom, S. R., & Patel, A. G. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9211-2 · Cited by 55
Self-citationEvans, S., Pamuklar, Z. N., Rosko, J., Mahaney, P., Jiang, N., Park, C., & Torquati, A. (2011) · Surgical Endoscopy · doi:10.1007/s00464-011-2004-7 · Cited by 60
“Indeed, exogenous administration of PYY [8, 9, 13] has been shown to increase satiety and decrease food intake, an effect which is additive with concomitant GLP-1 infusion [13].”
Gastrointestinal hormones, energy balance and bariatric surgery
Bueter, M., & le Roux, C. W. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.146 · Cited by 60
Duca, F. A., & Covașă, M. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512000529 · Cited by 57
“PYY may indeed have a role in the pathogenesis of obesity as diet-induced obese rats display reduced levels of PYY((166,167)), and human studies have shown a negative correlation between fasting PYY and BMI in adults((168)), as well as a”
BackgroundNew thoughts on managing obesity
Kopelman, P. G., & Grace, C. (2004) · Gut · doi:10.1136/gut.2003.021816 · Cited by 60
Negative Relationship between Fasting Plasma Ghrelin Concentrations and ad Libitum Food Intake
Salbe, A. D., Tschöp, M. H., DelParigi, A., Venti, C. A., & Tataranni, P. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032145 · Cited by 53
“Hormones that regulate food intake can be broadly separated into those that control body fat stores, e.g. insulin and leptin (24–26), and those that act as short-term satiety signals to initiate or end a meal, e.g. cholecystokinin (27), gut hormone PYY3–36 (28, 29), and ghrelin (9, 10).”
Background
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.